
Description | JK184 inhibits Gli in the Hedgehog (Hh) pathway with IC50 of 30 nM in mammalian cells. | |
---|---|---|
Targets |
| |
In vitro | JK184 antagonizes Hh signaling by inhibiting Gli-dependent transcriptional activity in a dose dependent manner. JK184 has a stronger inhibiting effects in mammalian cells with the IC50 of 30 nM compared with cyclopamine (IC50 = 250 nM)[1]. | |
In vivo | JK184 has a poor pharmacokinetic profile and bioavailability, because the half-life and Cmax of JK184 is lower compared with cyclopamine. JK184 micelles are a promising drug candidate for treating pancreatic tumors with high inhibitory effect on Hh activity[1]. |
ebiomall.com






>
>
>
>
>
>
>
>
>
>
>

